priorix pulveris un šķīdinātājs injekciju šķīduma pagatavošanai
glaxosmithkline biologicals s.a., belgium - vīruss rubellae, dzīves attenuatum, vīrusa, masalu gadījumi (pēcnācējiem schwarzi), dzīvo attenuatum, vīrusu parotitidis epidemici, dzīves attenuatum - pulveris un šķīdinātājs injekciju šķīduma pagatavošanai
neisvac-c 0,5 ml suspensija injekcijām pilnšļircē
pfizer europe ma eeig, united kingdom - meningokoku c grupas konjugēta vakcīna - suspensija injekcijām pilnšļircē - 0,5 ml
tetravet la 200 mg/ml šķīdums injekcijām
ceva sante animale,, francija - oksitetraciklīns - šķīdums injekcijām - 200 mg/ml - aitas; cūkas; kazas; liellopi
menquadfi
sanofi pasteur - neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid - meningīts, meningokoku - vakcīnas - menquadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w, and y. the use of this vaccine should be in accordance with available official recommendations.
adtralza
leo pharma a/s - tralokinumab - dermatīts, atopisks - citi dermatoloģiski preparāti - adtralza is indicated for the treatment of moderate to severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy.
typhim vi šķīdums injekcijām
sanofi pasteur europe, france - vēdertīfa polisaharīda vakcīna - Šķīdums injekcijām pilnšļircē
ebglyss
almirall, s.a. - lebrikizumab - dermatīts, atopisks - citi dermatoloģiski preparāti - ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.